Acute Gout Flare Treatment Market Growth Prospects, Competitive...

Acute Gout Flare Treatment Market Growth Prospects, Competitive Analysis, Trends and Forecast to 2030

Posted 2024-02-23 06:53:49

Market Dynamics:

The market for treating acute gout flare is poised to experience rapid revenue growth from 2019 to 2030, driven by a surge in clinical trials aimed at introducing new and safer treatment options.

Gout, characterized by inflammation in the joints due to elevated levels of uric acid, manifests as sudden and intense pain, redness, and swelling in affected joints, with the discomfort lasting from days to weeks.

While gout flare-ups commonly afflict the big toe, they can also affect other joints such as wrists, fingers, elbows, feet, ankles, and knees.

Get a sample copy of the Acute Gout Flare Treatment Market report: https://www.reportsanddata.com/download-free-sample/5671

Factors Supporting Market Growth:

Drivers:

Market revenue growth is fueled by increased research efforts to develop innovative anti-gout medications. For example, Arthrosi Therapeutics is initiating a phase 2 clinical trial in December 2019 to evaluate the safety and effectiveness of AR882, either alone or in combination with febuxostat or allopurinol, in gout patients. The trial is expected to conclude by June 2020.
Market expansion is further bolstered by the approval of new products by regulatory authorities. Additionally, the penetration of generic versions of anti-gout drugs is anticipated to create growth opportunities for market players seeking to expand their presence in the gout disease treatment market.

Restraints:

Opportunities:

The increasing prevalence of cancer has led to a growing demand for effective treatments, prompting global companies to invest significantly in research and development (R&D) to develop advanced drugs. The market is also expected to benefit from the development of sophisticated pharmaceutical delivery systems awaiting FDA approval, driven by the rising demand for cutting-edge medications to treat conditions like malignant mesothelioma.

Geographic Market Scenario:

Region with Largest Revenue Share:

North America is projected to dominate the market during the forecast period, driven by the presence of major players, widespread usage of gout treatment, high prices of name-brand medications in the U.S., and the introduction of urate-lowering medicines.

Region with Fastest Revenue Growth Rate:

The Asia Pacific region is expected to witness the highest compound annual growth rate (CAGR) during the forecast period, attributed to its high prevalence rate of gout, increasing healthcare expenditure, and adoption of newer technologies and therapies driving market revenue growth.

Key Market Trends and Innovation:

Novartis Pharmaceuticals is currently conducting a phase 3 clinical trial to assess the safety and efficacy of Canakinumab 150mg in patients with acute gouty arthritis.
A phase 2 clinical trial is underway to evaluate the effectiveness of Anakinra 100mg in patients with acute gout flare and Chronic Kidney Disease.
GeneScience Pharmaceuticals Co., Ltd. is conducting a phase 1 clinical trial on Genakumab for treating patients with acute gout flare.

Organic and Inorganic Strategies Adopted:

In December 2021, the FDA approved the use of Lesinurad (Zurampic) in combination with allopurinol or febuxostat for the treatment of hyperuricemia associated with gout flare.
In December 2018, SunGen Pharma received FDA approval for Prednisone (Deltasone), available in various strengths (10 mg, 20 mg, and 50 mg tablets), for the treatment of various conditions including arthritis, gout, blood disorders, immune system disorders, among others.

Major Companies in the Market:

Key players include Savient Pharmaceuticals, Takeda Pharmaceutical Company Ltd., Novartis AG, AstraZeneca plc., Merck & Co., Inc., Teijin Pharma Ltd., and Regeneron Pharmaceuticals.

Report Offerings:

The report provides historical data, forecasts, and revenue growth analysis at a global, regional, and country level from 2019 to 2030. It offers insights into industry trends, drivers, restraints, opportunities, threats, market strategies, segment revenue, and revenue share contributions by each regional and country market. Additionally, the report includes industry analysis, competitive landscape, company financials, and impact analysis.

Drug Class Outlook: